课题基金 / 基金详情

Rules of gene expression modeled on human dendritic cell response to pathogens

Rules of gene expression modeled on human dendritic cell response to pathogens
模拟人类树突状细胞对病原体反应的基因表达规则
批准号:
8991717
负责人:
Manuel Garber
金额:
$201.23万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-01-05 至 2017-11-30

项目摘要

项目成果

Manuel Garber的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The developmental shifts that occur when cells respond to environmental stimuli are controlled in large part by gene expression programs involving thousands of genes. Transcription factors (TFs), chromatin modifying enzymes, and cis-acting DNA elements contribute to the networks that underlie such programs. The code that links these variables in such a way that the expression of a given gene can be predicted based on the presence of specific components has yet to be deciphered. A model for such a code will be constructed here based on genome-wide analysis of human dendritic cells (DCs) as they mature in response to pathogens. DCs are antigen-presenting cells that initiate and determine the quality and magnitude of the host immune response. Recent technical advances in stem cell biology, reverse-genetic tools for primary human cells, and genome-wide assessment of transcripts, local chromatin features and long-range chromatin interactions, will be exploited here to construct a model for the transcriptional regulatory network that underlies pathogen detection and maturation in human DCs. In Aim 1, DCs will be sampled in a time-course following stimulation with LPS. Stimulation-responsive genes will be identified by RNA-Seq. Chromatin features will be mapped using ChIP-Seq, high-resolution global DNA foot printing, and Hi-C. This systematic map of all responsive genes and the regulatory regions associated with them will be combined with known DNA-binding motifs to generate an initial model for the gene regulatory network. In Aim 2 sixty transcription factors that drive transcription within the first 2 hrs of LPS stimulation will be identified from the model in Aim 1. These factors will be knocked-down in hDCs and the effect on the LPS response will be assessed using RNA-Seq. This functional data for each TF will be complemented by measurement of protein-DNA interactions using ChIP- Seq; the later will exploit CRISPR technology to fuse a common epitope tag to endogenous coding sequences for these TFs. By pinpointing key transcription factors, their binding sites, and transcriptionally-responsive genes, this analysis will be used to refine the model for the gene regulatory network. In Aim 3, a subset of cis- acting regulatory regions important for controlling the hDC transcriptional response to LPS will be identified using features collected in the previous aims. Selected loci will be perturbed using CRISPR technology and effects on target gene expression will be examined. The effect on gene expression of allelic variants in relevant loci will be assessed, using published data as well as 300 human samples that will be genotyped using Pac- Bio. In conjunction, the variance in the higher-order chromatin conformation for 50 key regulatory loci across five individuals will be assessed by 5C. These data will be used to further refine our regulatory model. The result of this analysis will be a model that highlights the key transcription factors and cis-acting components that drive gene expression in LPS-stimulated human DCs. Our findings are expected to provide a more general method for identifying the genetic determinants of gene expression in primary mammalian cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Predictive drivers of new onset, relapse, and progression of human autoimmunity in skin
Cell-Cell Communications and Tissue Memory in Vitiligo
Cell-Cell Communications and Tissue Memory in Vitiligo
Predictive Modeling of the Functional and Phenotypic Impacts of Genetic Variants
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究